Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (661-670 of 755) with videos related to

Pageof 76
Sort By:
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Rheumatology (Oxford, England)|June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trialD E Furst, P J Clements, W K Wong, et al.
Arthritis and Rheumatism|November 18, 2000
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trialP J Clements, E L Hurwitz, W K Wong, et al.
Arthritis and Rheumatism|March 27, 2001
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trialP J Clements, W K Wong, E L Hurwitz, et al.
Annals of the Rheumatic Diseases|February 4, 2019
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018Kevin L Winthrop, Michael E Weinblatt, Mary K Crow, et al.
Journal of Scleroderma and Related Disorders|August 25, 2025
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc CommitteeNancy Maltez, Laura Ross, Murray Baron, et al.
The Lancet. Rheumatology|January 24, 2024
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohortMuriel Elhai, Nanthara Sritharan, Marouane Boubaya, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signaturesShervin Assassi, Xuan Wang, Guocai Chen, et al.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Annals of the Rheumatic Diseases|October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Pageof 76

Showing results (661-670 of 755) with videos related to

Sort By:
Pageof 76
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Rheumatology (Oxford, England)|June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trialD E Furst, P J Clements, W K Wong, et al.
Arthritis and Rheumatism|November 18, 2000
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trialP J Clements, E L Hurwitz, W K Wong, et al.
Arthritis and Rheumatism|March 27, 2001
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trialP J Clements, W K Wong, E L Hurwitz, et al.
Annals of the Rheumatic Diseases|February 4, 2019
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018Kevin L Winthrop, Michael E Weinblatt, Mary K Crow, et al.
Journal of Scleroderma and Related Disorders|August 25, 2025
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc CommitteeNancy Maltez, Laura Ross, Murray Baron, et al.
The Lancet. Rheumatology|January 24, 2024
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohortMuriel Elhai, Nanthara Sritharan, Marouane Boubaya, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signaturesShervin Assassi, Xuan Wang, Guocai Chen, et al.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Annals of the Rheumatic Diseases|October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Pageof 76